AG
RARE icon

Advisor Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Advisor Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$14K Sell
345
-1,159
-77% -$47.8K ﹤0.01% 4153
2019
Q3 		$65K Buy
1,504
+1,123
+295% +$61K ﹤0.01% 3197
2019
Q2 		$24K Sell
381
-10
-3% -$636 ﹤0.01% 3870
2019
Q1 		$27K Buy
391
+87
+29% +$4.97K ﹤0.01% 3806
2018
Q4 		$13K Buy
304
+39
+15% +$2.13K ﹤0.01% 4069
2018
Q3 		$20K Buy
265
+182
+219% +$14.8K ﹤0.01% 3906
2018
Q2 		$6K Sell
83
-1
-1% -$65 ﹤0.01% 4314
2018
Q1 		$4K Sell
84
-5
-6% -$252 ﹤0.01% 4506
2017
Q4 		$4K Buy
89
+40
+82% +$1.96K ﹤0.01% 4505
2017
Q3 		$3K Sell
49
-83
-63% -$4.92K ﹤0.01% 4439
2017
Q2 		$8K Sell
132
-6
-4% -$361 ﹤0.01% 4046
2017
Q1 		$9K Sell
138
-102
-43% -$7.77K ﹤0.01% 3846
2016
Q4 		$16K Hold
240
– – ﹤0.01% 3367
2016
Q3 		$16K Buy
240
+198
+471% +$12.6K ﹤0.01% 3298
2016
Q2 		$1K Buy
+42
New +$2.72K ﹤0.01% 4261

Other funds holding RARE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Advisor Group's RARE Position: Q4 2019 in Review

Advisor Group reduced its Ultragenyx Pharmaceutical (RARE) stake by 77% in Q4 2019, selling an estimated $47.8K and leaving 345 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

Advisor Group first reported a position in RARE in Q2 2016 and has held it in 15 quarters since. The position peaked at $65K in Q3 2019. 173 funds tracked by Wall St. Rank hold RARE as of Q4 2019.

  • Advisor Group held 345 shares of Ultragenyx Pharmaceutical worth $14K as of Q4 2019.
  • Advisor Group sold 1,159 Ultragenyx Pharmaceutical shares in Q4 2019, an estimated $47.8K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4153 holding.
  • Advisor Group first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Ultragenyx Pharmaceutical position peaked at $65K in Q3 2019.
  • 173 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.